India is emerging as a favourable destination to conduct clinical trials: PwC-USAIC Report
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Pheezee is designed to assess musculoskeletal and neuromuscular health.
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Specialty Chemicals grew 38% YoY for FY23
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated